Alemtuzumab
- Generic Name
- Alemtuzumab
- Brand Names
- Campath, Lemtrada, MabCampath
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216503-57-0
- Unique Ingredient Identifier
- 3A189DH42V
- Background
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...
- Indication
用于烷化剂氟达拉滨（fludarabine）治疗失败的B细胞性慢性淋巴细胞白血病患者；亦可用于复发缓解型多发性硬化症治疗。
- Associated Conditions
- B-Cell Chronic Lymphocytic Leukemia, Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Steroid Refractory Acute Graft Versus Host Disease, T-cell Prolymphocytic Leukemia (T-PLL), Refractory Autoimmune Hemolytic Anemia, Refractory Idiopathic thrombocytopenic purpura
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2006-06-13
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Tawam Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00336206
Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
- Conditions
- Interventions
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 222
- Registration Number
- NCT00331162
- Locations
- 🇺🇸
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
- First Posted Date
- 2006-05-26
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 29
- Registration Number
- NCT00330252
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2017-01-20
- Target Recruit Count
- 24
- Registration Number
- NCT00323323
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Simultaneous Pancreas-kidney Transplantation With Campath Protocol
- Conditions
- Interventions
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2012-06-19
- Lead Sponsor
- Dr. Claudia Bösmüller
- Target Recruit Count
- 30
- Registration Number
- NCT00316810
- Locations
- 🇦🇹
University Hospital Innsbruck, Innsbruck, Tyrol, Austria
A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion
- Conditions
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2009-12-16
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Registration Number
- NCT00292760
Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2017-06-08
- Target Recruit Count
- 136
- Registration Number
- NCT00260689
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- EMagnusson
- Target Recruit Count
- 123
- Registration Number
- NCT00246129
- Locations
- 🇬🇧
West London Renal and Transplant Centre, 4th Floor Ham House, Hammersmith Hospital, London, United Kingdom
Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
- Conditions
- Interventions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2017-01-02
- Target Recruit Count
- 35
- Registration Number
- NCT00240994
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Children's Hospital, Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital, Boston, Boston, Massachusetts, United States
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Steven E. Coutre
- Target Recruit Count
- 25
- Registration Number
- NCT00230282
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.